|1.||Järvinen, Tomi: 5 articles (10/2007 - 01/2004)|
|2.||Mäntylä, Antti: 5 articles (10/2007 - 01/2004)|
|3.||Garnier, Tracy: 4 articles (10/2007 - 01/2004)|
|4.||Croft, Simon L: 3 articles (01/2007 - 01/2004)|
|5.||Rautio, Jarkko: 3 articles (10/2004 - 01/2004)|
|6.||Nevalainen, Tapio: 3 articles (10/2004 - 01/2004)|
|7.||Vepsälainen, Jouko: 3 articles (10/2004 - 01/2004)|
|8.||Mhadhbi, Moez: 2 articles (01/2015 - 05/2010)|
|9.||Darghouth, Mohamed Aziz: 2 articles (01/2015 - 05/2010)|
|10.||Shah, Akram: 1 article (07/2015)|
07/06/2012 - "Buparvaquone is very effective in the treatment of Theileria infections in cattle. "
08/01/1992 - "Buparvaquone, at the dosage evaluated, had transitory therapeutic efficacy against acute B equi infection in splenectomized horses, but was unable alone to clear carrier infection."
05/01/1989 - "Buparvaquone given at the rate of 4 to 6 mg/kg IV and/or IM was therapeutically effective in 4 of 5 acute B equi infections in splenectomized ponies. "
07/17/1998 - "A clinical trial testing the prophylactic effect of a 5 mg kg-1 dose of buparvaquone on either Theileria annulata or Theileria parva experimental infections of calves demonstrated its efficacy for periods of at least seven days. "
08/01/1992 - "We evaluated the efficacy of buparvaquone in eliminating infection with Babesia equi of European origin in carrier horses and in splenectomized horses with experimentally induced acute infection. "
01/01/2008 - "[Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis]."
05/01/1998 - "Buparvaquone (Butalex), a therapeutic for theileriosis, has been shown to have anti-leishmanial activity in vitro. "
01/01/2008 - "The aim of this study was to examine the efficacy of buparvaquone (Buparvon, ALKE, Istanbul) in the treatment of theileriosis in cattle. "
07/06/2012 - "The present study reported an outbreak of bovine tropical theileriosis in Fars Province, southern Iran with buparvaquone treatment failure associated with mutations in drug-binding sites of its causative agent. "
05/11/2010 - "The present study describes an outbreak of tropical theileriosis cases refractory to buparvaquone treatment, which occurred in a small-size dairy farm in Tunisia. "
07/01/2015 - "The study proposes that buparvaquone may be further investigated as a candidate drug for treatment of cutaneous leishmaniasis."
01/01/2007 - "Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis."
01/01/2004 - "In addition, 4b easily released the parent drug in human skin homogenate and, therefore, is a promising prodrug candidate to deliver buparvaquone through the skin for the treatment of cutaneous leishmaniasis."
10/01/2007 - "The efficacy of different formulations of the naphthoquinone buparvaquone and two phosphate prodrugs in in vivo models of both visceral and cutaneous leishmaniasis is described. "
01/01/2007 - "As the part of a study to develop buparvaquone (BPQ) formulations for the treatment of cutaneous leishmaniasis, the topical delivery of BPQ and one of its prodrugs from a range of formulations was evaluated. "
|4.||Body Weight (Weight, Body)
06/30/2006 - "Thirty-two cattle (56%) received single-dose treatment (2.5 mg buparvaquone per kg body weight), while two and three-dose treatment with interval(s) of 48 h was given to 33% and 11% of total treated cattle, respectively; 38 cattle (60.3%) were treated at an early stage of the disease, while 25 cattle (39.7%) were treated at an advanced stage of the disease. "
05/01/1999 - "Buparvaquone (2.5 mg/kg body weight) was administered to animals in the second group. "
05/01/1989 - "When administered at the rate of 2.5 mg/kg of body weight, IM, 4 times at 96-hour intervals, buparvaquone was effective in eliminating B equi carrier infection in 1 horse. "
08/01/1992 - "When administered at the rate of 5 mg/kg of body weight, IV, 4 times at 48-hour intervals, buparvaquone prompted rapid abatement of parasitemia. "
10/01/1989 - "Buparvaquone at a dose of 2.5 mg kg-1 body weight was given as a single injection (intramuscularly) on Day 0 (Group 1), Day 8 (Group 2) and Day 12 (Group 3) post-infection. "
|5.||Visceral Leishmaniasis (Kala Azar)
07/01/2004 - "Novel oxime derivatives (2, 3 and 5) of buparvaquone (1) and O-methyl-buparvaquone (4) were synthesized and their in vitro activities against Leishmania donovani, the causative agent of visceral leishmaniasis (VL), were determined. "
01/01/2004 - "Water-soluble phosphate prodrugs of buparvaquone (1), containing a hydroxynaphthoquinone structure, were synthesized and evaluated in vitro for improved topical and oral drug delivery against cutaneous and visceral leishmaniasis. "
|1.||Drug Therapy (Chemotherapy)